Capstone Investment Advisors
GALT icon

Capstone Investment Advisors’s Galectin Therapeutics GALT Stock Holding History

Capstone Investment Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-42,260
Closed -$164K – 1936
2021
Q3 		$164K Buy
+42,260
New +$143K ﹤0.01% 1723

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capstone Investment Advisors's GALT Position: Q4 2021 in Review

Capstone Investment Advisors sold out of Galectin Therapeutics (GALT) in Q4 2021, closing a stake of 42,260 shares — an estimated $164K sold.

Capstone Investment Advisors first reported a position in GALT in Q3 2021 and held it in 1 quarter. The position peaked at $164K in Q3 2021. 55 funds tracked by Wall St. Rank hold GALT as of Q4 2021.

  • Capstone Investment Advisors reported no remaining Galectin Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 42,260 Galectin Therapeutics shares in Q4 2021, an estimated $164K.
  • Capstone Investment Advisors first reported a position in Galectin Therapeutics in Q3 2021 and held it in 1 quarter.
  • Capstone Investment Advisors's Galectin Therapeutics position peaked at $164K in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2021.

Based on Capstone Investment Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.